Corporate Information – Page 3

iZafe opens up more sales channels for Dosell consumer

iZafe Group AB ("iZafe Group") announces today that they are now removing exclusive sales of Dosell via Apoteket.se and are instead opening up to future sales via several sales channels. This after receiving great international impact for their pharmaceutical robot and now having volume commitments from several countries, including the UK, Holland, Portugal and Spain.

iZafe has also started dialogues with several pharmacies regarding selling Dosell as a consumer product and will therefore initially sell Dosell on its own website Dosell.se, before it is gradually sold via more partners. The introductory offer on the hardware remains SEK 499 until the last of May, before the price is raised to SEK 1,999. The monthly fee of SEK 299 will be maintained.

"The launch of the consumer version has been a determining factor in being able to sign the partners we have now started this year with. We are very happy about the great international interest for Dosell and look forward to opening up more sales channels. Our goal is to make Dosell available to as many people as possible who need help managing their medication." says Anders Segerström, CEO of iZafe Group.

For more information about Dosell, visit Dosell.se.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution and the connected dose bag Pilloxa. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafe.se/investor-relations/.

iZafe opens up more sales channels for Dosell consumer

iZafe Group signs agreement with Ti-Medi in Spain worth minimum of SEK 12 million

iZafe Group AB ("iZafe Group") is pleased to announce that it has signed a collaboration agreement with Ti-Medi for the rights to sell and market the medication robot Dosell. Ti-Medi's minimum commitment over a four-year period is worth minimum SEK 12 million.

The first phase of the collaboration will start in October 2023, with the aim of ensuring the entire sales process and launching a unique concept from January 2024. The commitment is to sell at least 1,800 Dosell devices over four years. The revenue will gradually increase from the license revenue generated in connection with the launch in January 2024.

Ti-Medi is a global company that manufactures and distributes technical solutions for medication management compliance. Ti-Medi sells dose packaging machines to over 650 pharmacies in Spain and Portugal.

"We are pleased to welcome Ti-Medi as both a major shareholder and now also as a partner. Their broad experience in the pharmaceutical industry and their strong presence in the market make them an ideal partner to expand our sales of Dosell," says Anders Segerström, CEO of iZafe Group.

Over the last ten years, Ti-Medi has delivered technological solutions to healthcare professionals to make the management of Multi-Dosage Systems easier, safer, and more efficient. Currently, the company aims to offer technological solutions to patients as well.

"One in every two patients does not take their medication properly! We are pharmacists, and we truly believe in the role of the community pharmacy as a key player in the medication compliance challenge we are currently facing. With this partnership with Dosell, we aim to extend our value proposition to the end-patient, improving their quality of life by making it easier to manage their medication," says Marc Tarruell, Co-Founder of Ti-Medi.

For more information, please visit Ti-Medi's website, www.ti-medi.com/en.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group signs agreement with Ti-Medi in Spain worth minimum of SEK 12 million

iZafe Group signs an agreement with a new partner in Portugal with a value of at least SEK 12.2 million

iZafe Group AB ("iZafe Group") hereby announces that the company has signed a cooperation agreement with MDM Pulse for the right to sell and market the pharmaceutical robot Dosell in Portugal. MDM Pulse's minimum commitment over a five-year period amounts to SEK 12.2 million to subsequently generate a recurring license income of at least SEK 4.2 million annually.

"We are very happy to have started this collaboration with MDM Pulse and thereby reach a new market in Europe for our pioneering pharmaceutical robot, Dosell. This collaboration represents a great opportunity for iZafe Group to continue driving innovation in the healthcare sector, also internationally. We look forward to working together with MDM Pulse to meet the needs of patients and healthcare providers in the Portuguese market and strengthen our position as a leading innovator in the industry.” says Anders Segerström, CEO of iZafe Group

MDM Pulse – Healthcare Solutions is a Portuguese company founded in 2006 that distributes medical technology products. The company has more than 20 years of experience in the IVD and pharmaceutical sectors. MDM Pulse has received several awards from business partners for its innovative and entrepreneurial approach, and has also been recognized by some of the most prestigious public institutions.

"By increasing patient safety and improving treatment adherence, Dosell provides an innovative solution that meets the challenges of Portugal's growing elderly population and the resulting increase in pharmaceutical drug consumption. Launching in Q3 this year, we will focus on the B2C market, and then expand to B2B market. Our partnership with iZafe represents an important milestone in closing the healthcare gap and promoting healthcare in Portugal." says Paula Matos, founder and CEO of MDM Pulse

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group signs an agreement with a new partner in Portugal with a value of at least SEK 12.2 million

iZafe Group AB gets a new international strategic shareholder

iZafe Group AB ("iZafe Group" or the “Company”) hereby announces that that the Spanish company Ti-Medi has acquired approximately five percent of the shares in the Company, which makes Ti-Medi one of iZafe Group's largest shareholders. Ti-Medi has in total acquired 12,529,309 shares at the price of SEK 0.29 per share through a block deal brokered by Mangold Fondkommission.

Ti-Medi is a global company active in the manufacturing and distribution of technical solutions for compliance in pharmaceutical management. Ti-Medi sells dose packaging machines to over 650 pharmacies in Spain and Portugal.
For more information, see Ti-Medi's website, www.ti-medi.com/en.

"Our assessment is that the demand for iZafe Group's products and services will increase in the markets where we operate. We have long been looking for a company that develops and offers its customers precisely these types of services. Therefore, we have decided to invest in iZafe Group and we also hope to be able to find a good collaboration in the future to bring iZafe's products and services into Ti-Medi's product range in order to be able to offer these to our customers," says Marc Tarruell Tibau, co-founder of Ti-Medi

"The company has now gained a new strong and long-term owner that contributes with expertise and a global network. We view this very positively and interpret the investment as proof that iZafe Group's product and operations have support among knowledgeable market colleagues. We look forward to sharing the knowledge that Ti-Medi possesses about distribution in Southern Europe and initiating discussions about a future collaboration", says Anders Segerström, CEO of iZafe Group AB

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

iZafe Group AB gets a new international strategic shareholder

iZafe Group is now also available on the fintech platform Eucaps.com

As part of the internationalization strategy, iZafe Group has entered into a collaboration with the fintech platform eucaps.com. This is to facilitate the dissemination of information and dialogue with existing shareholders and to be able to reach out to new investors outside Sweden's borders.

"Eucap's platform offers opportunities for us at iZafe Group to drive international interest in our share, while at the same time we can easily interact and keep our existing owners updated on our development," says Anders Segerström CEO of iZafe Group AB and continues: "The internationalization of our business has taken off and as a step in the process we want to offer better conditions for international investors to follow our company and our share, which hopefully means increased international attention and new investors."

Eucap's platform offers global transparency and market access for companies in the European small-cap segment, which means, among other things, that companies traded on the Swedish stock exchange First North become accessible to investors from all over Europe. Eucaps ensures that investors have full access to accurate information, reports, stock prices, ownership data, news, etc.

"We are happy that iZafe has chosen to grow with us. Our goal is to make the opportunities in the European small-cap market visible to investors from all over the world. At the same time, we want to prevent market manipulation and create better liquidity and pricing for these companies," says Henrik Wagenius, CEO and founder of Eucaps.

To follow iZafe Group AB in Eucaps go to the following link: https://eucaps.com/izafe-group

About iZafe Group AB (publ.)

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell and SaaS platform Pilloxa with smart pillbox are used to reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

iZafe Group is now also available on the fintech platform Eucaps.com

Warrants of series TO13B were subscribed to approximately 81.7 percent and iZafe Group receives approximately SEK 19.4 million

iZafe Group AB (”iZafe Group” or the ”Company”) today announces the outcome of the exercise of warrants of series TO13B, which were issued in the fourth quarter of 2022. In total, 96,805,841 warrants of series TO13B were exercised, corresponding to approximately 81.7 percent of the total number of outstanding warrants of series TO13B, for subscription of 96,805,841 B-shares at a subscription price of SEK 0.20 per B-share. iZafe Group will receive approximately SEK 19.4 million before issuing costs through the exercise of the warrants of series TO13B.

"I want to start by thanking our shareholders for their great support for iZafe Group, something that is made clear from the outcome of the warrants program. The company is facing a commercial breakthrough with a strong international interest in Dosell which will now be sold in large volumes, something we have been working on for a very long time. At the same time, we have greatly reduced our development costs and with the proceeds from the warrants, our assessment is that the Company's liquidity needs are satisfied up until cash flow positivity. I look very positively at 2023 and the position we are in. I want to thank all our employees, shareholders, and partners who made it possible.” – Anders Segerström, CEO iZafe Group

Background

The subscription period for exercise of the warrants of series TO13B took place from February 23, 2023, up to and including March 8, 2023. The subscription price per B-share for exercising the warrants of series TO13B was set to SEK 0.20.

In total, 96,805,841 warrants of series TO13B were exercised for subscription of 96,805,841 B-shares, meaning that approximately 81.7 percent of all outstanding warrants of series TO13B were exercised for subscription of B-shares.

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to B-shares within approximately three (3) weeks.

Number of shares, share capital and dilution

Through the exercise of the warrants of series TO13B, the number of shares in iZafe Group increases by 96,805,841 B-shares, from 153,780,330 shares (consisting of 600,000 A-shares and 153,180,330 B-shares) to a total of 250,586,171 shares. The share capital will increase by SEK 19,361,168.20 from SEK 30,756,066.00 to SEK 50,117,234.20.

For existing shareholders who did not exercise any warrants of series TO13B, the dilution amounts to approximately 38.6 percent of the number of shares and approximately 37.8 percent of the number of votes in the Company.

Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO13B.

About iZafe Group AB (publ.)

Warrants of series TO13B were subscribed to approximately 81.7 percent and iZafe Group receives approximately SEK 19.4 million

iZafe’s subsidiary Pilloxa signs a cooperation agreement with Chiesi in Germany with a value of SEK 1 million

iZafe Group (publ.) hereby announces that its wholly owned subsidiary Pilloxa AB is expanding its digital support for patients to Germany in collaboration with Chiesi´s local office. The implementation of the service will have an initial allowance of SEK 222 thousand of the total contract value of SEK 1 million for the 3 years agreement.

The goal of the initiative is to empower patients to take control of their treatment journey and improve their quality of life. Pilloxa's app allows patients to track their medication intake and symptoms, set reminders, and generate reports to share with healthcare providers. By using the app, patients can gain a better understanding of their treatment and make informed decisions about their care.

As part of the collaboration, Pilloxa will be providing Chiesi with anonymized data. This data will give Chiesi deep insights into patient adherence, which is critical in managing rare diseases. By working together, Pilloxa and Chiesi aim to improve patient outcomes and advance the field of rare disease treatment.

"We are excited to collaborate with Chiesi's local office in Germany to expand access to our digital support solution for patients. As our business model is based on recurring revenue for each country and therapeutic area, we look forward to broadening our collaboration to more areas and countries together with Chiesi." says Helena Rönnqvist, CMO iZafe Group & BUM Pillbox.

"We look forward to supporting all patients in germany with their treatment. The goal of this initiative is to provide as much support as we can to patients in dealing with their disease’s burden. Of the various functions of the app especially the “reports” will be of great help to patients and HCPs since both can rely on long-term information and be on the same side while speaking about the treatment and the improvement in daily life. Finally the anonymized data can give us a deep insights into adherence, which we really need in rare disease." says Mahmoud Alsani, Product Manager Rare Disease, German Office of Chiesi Global Rare Diseases.

About Chiesi Group
Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.

By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making.
With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 30 countries, and counts more than 6,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For further information please visit www.chiesi.com.

About Pilloxa
Pilloxa is a Swedish company that works to develop apps for patients to support them in adherence to their treatment and to connect patients, healthcare providers and the pharmaceutical industry. The company provides a SaaS platform where pharmaceutical companies and other customers can design digital patient support quickly, securely and at a low cost. Connected aids such as Pilloxa's self-developed smart medication dose can also be connected to the service to support patients in taking the correct medication. Customers and partners include pharmaceutical companies such as Bayer Nordics and the Nordic office of Chiesi Global Rare Diseases, university hospitals such as the University Hospital in Oslo and universities such as the University of Gothenburg.
Read more on pilloxa.com

About iZafe Group AB (publ.)

iZafe's subsidiary Pilloxa signs a cooperation agreement with Chiesi in Germany with a value of SEK 1 million

The last day of trading in the warrants of series TO13B in iZafe Group AB is today, March 6, 2023

Today, March 6, 2023, is the last day of trading with the warrants of series TO13B in iZafe Group AB (“iZafe” or “the Company”). The subscription period for the warrants of series TO13B runs up until March 8, 2023. Each warrant of series TO13B gives the owner the right to subscribe for one (1) new share of series B in iZafe. The exercise price for the warrants of series TO13B is SEK 0.20 per share of series B.

If all the warrants of series TO13B are exercised, the Company will receive approximately SEK 23.7 million before issuing costs. In order to prevent the warrants expiring without value, the holder must actively subscribe for new shares, no later than March 8, 2023. Alternatively, the holder may sell the warrants, no later than today, March 6, 2023. Please be aware that certain nominees may close their subscriptions earlier than March 8, 2023. Complete terms and conditions for the warrants are available on the Company’s website, www.izafegroup.com.

Summarized terms for the warrants of series TO13B:

Exercise period: February 23, 2023 – March 8, 2023.

Exercise price: SEK 0.20 per share of series B.

Issue size: 118,556,833 warrants of series TO13B, which entitles to subscription of 118,556,833 shares of series B. If all the warrants are exercised, the Company will receive approximately SEK 23.7 million before issuing costs.

Last day for trading warrants of series TO13B: March 6, 2023.

Share capital and dilution: If all warrants are exercised the share capital will increase with SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. If all warrants are exercised the number of shares will increase with 118,556,833 shares of series B, in total the number of shares in the Company will increase from 153,780,330 shares to 272,337,163 shares (600,000 shares of series A and 271,737,163 shares of series B). The dilution at full exercise of all warrants amounts to approximately 43.53 percent of the number of shares and 42.69 percent of the votes in the Company.
Note that the warrants of series TO13B that are not exercised at the latest March 8, 2023, or sold at the latest March 6, 2023, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please note that some trustees may close their registration earlier than 8 March 2023.

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

The last day of trading in the warrants of series TO13B in iZafe Group AB is today, March 6, 2023

iZafe Group signs agreement with new partner in the United Kingdom worth at least SEK 18.7 million.

iZafe Group AB ("iZafe Group") hereby announces that the company has signed an exclusive collaboration agreement with Targeted Outcomes for the rights to sell and market the pharmaceutical robot Dosell in the United Kingdom for a period of 5 years. Targeted Outcomes' minimum commitment over a five-year period amounts to SEK 18.7 million, after which a recurring license revenue of at least SEK 7.9 million annually will be generated.

Targeted Outcomes' annual minimum commitment for the purchase of Dosell increases annually during the agreed 5-year period. The minimum agreed sales volume amounts to a total of 1,810 Dosell units.

"We are pleased that more players want to take part in our products outside of Sweden. The United Kingdom is a very interesting market with great potential, expected to show increased demand for digital aids for safer medication at home. We have long been searching for the right partner to enter the UK market. The choice to collaborate with Targeted Outcomes is due, among other things, to their solid experience in medical technology and their broad industry contacts," says Anders Segerström, CEO of iZafe Group.

Targeted Outcomes is a medication management company that helps patients and prescribers better adhere to medication regimens and thus improve patients' health. The company was founded by Andrew Burr, an independent prescriber and clinical pharmacist with experience in implementing medication management programs in both private and public health sectors, and Andy Beesley, with experience in helping pharmacies distribute automated solutions to improve medication adherence.

"The agreement with Dosell supports a range of initiatives that will begin in 2023 to test the service in home care, nursing homes, and virtual care wards. The most expensive medication for the NHS is the one the patient is prescribed but does not take. If we succeed in improving medication adherence, we will directly improve the outcomes patients experience. Dosell has enormous potential to achieve this and improve pharmacists' contribution to patient care overall," says Andrew Burr.

"Our agreement with Dosell enables Targeted Outcomes to deliver a truly innovative and cost-effective solution. Through collaborations, we aim to prove that a holistic approach to medication management by bringing together pharmacies, care agencies, and service users will deliver benefits for all parties," says Andy Beesley.

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

iZafe Group signs agreement with new partner in the United Kingdom worth at least SEK 18.7 million.

AAA IMG 0022

iZafe Group announces exclusive agreement to sell 1,000 Dosell annually

iZafe Group AB ("iZafe Group") announce that it has signed an exclusive partnership agreement with IVE Ventures (“IVE”) for the right to exclusively sell and market the Dosell medication robot in the Netherlands. IVE has committed to purchasing a minimum of 1,000 Dosell units annually for a three-year period in order to maintain exclusivity. The total value of hardware purchases and licensing revenue amounts to approximately SEK 16 million for the first three years, with an annual recurring licensing revenue of at least SEK 6 million thereafter.

IVE has placed an initial order for 1,000 Dosell units and has a minimum commitment of 1,000 Dosell units per year to maintain exclusivity for the Netherlands.

IVE has been offering a range of connected health services since 2014. In recent years, IVE has expanded its portfolio to include products from Teltonika, Vayyar, Vivago, Eview, and Withings. IVE has chosen to include Dosell in its portfolio in order to expand its range with a groundbreaking digital medication robot. By distributing Dosell, IVE can better support its existing care and alarm center customers in the Netherlands with a reliable and proven safe medication solution. IVE aims to commercially launch Dosell in the Dutch market in the second quarter of 2023.

“This agreement is another great step forward for IVE. We have been assessing the market of providing safe and reliable medication dispensing for the past 24 months. When meeting Dosell, we quickly realized that they share the same vision to provide reliable connected health solutions. The short integration time for market introduction, that lasted only 8 weeks, solidifies our believe that our shared DNA will allow us to act and react agile on the challenges which the Healthcare industry faces today. Dosell covering a key part of our connected health portfolio, allowing us to fulfil our mission: keeping our loved ones independent and safe in the easiest, surest and most economical way.” Says Martijn Van Bree, Managing Director of IVE Ventures.

"Since we launched a consumer version of our medication robot Dosell, we have received great demand internationally. I am very pleased that we are reaching this important milestone. Breaking into the Dutch market, which is the market that has come the furthest in packaging medicine in sachets, is significant. That IVE also chooses to invest heavily in our medication robot Dosell after reviewing all competitors in the market is also a testament to the strength of Dosell's potential for international success," says Anders Segerström, CEO of iZafe Group.

About IVE Ventures

IVE Ventures was founded in 2014 to invest into, distribute and operate a range of connected services within the Smart Mobility and Connected Health sector. Within the group, IVE’s subsidiaries include a service provider for connected health services (ICE Alarm the Netherlands), a 24/7 multilingual Medical Service Center (ICE Alarm España) and a provider of smart mobility solutions for insurance companies (ICE Protect the Netherlands). Operating out of offices in both the Netherlands and Spain, IVE is trusted by several major insurance and security companies who rely on IVE to provide mission-critical solutions to its clients.